PLC Activator Composition for Alzheimer's Disease Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapeutic methods for Alzheimer's disease primarily focus on alleviating symptoms rather than addressing the underlying cause, and there is a need for a material that can prevent, delay, or treat the onset of the disease.

Innovation Solution

A pharmaceutical composition comprising a phospholipase C (PLC) activator as an active ingredient, which restores the endocannabinoid mobilization suppressed by amyloid beta oligomers, recovers spike timing-dependent long-term potentiation in the hippocampus, and normalizes PLCβ1 protein levels.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Object-affected harmful factors

If current therapeutic methods are used, then symptoms can be alleviated, but the underlying cause of Alzheimer's disease cannot be addressed

Engineering Contradiction:

Improvesymptom alleviationVSAvoiddisease prevention capability

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent identifies amyloid beta oligomers as harmful factors that suppress endocannabinoid mobilization and PLCβ activity. By targeting this specific harmful mechanism with a PLC activator, the invention converts the understanding of disease pathology into a therapeutic opportunity, restoring normal signaling pathways that are suppressed by amyloid beta aggregates.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The invention changes the functional state of phospholipase C by using an activator that increases PLCβ activity. This parameter change (from suppressed to active state) restores endocannabinoid mobilization and synaptic plasticity, directly addressing the underlying cause rather than merely alleviating symptoms.

Inventive Principle:

Principle #35Parameter changes

2Quantity of substance

If amyloid beta oligomers are present, then Alzheimer's disease pathology occurs, but endocannabinoid mobilization is suppressed

Engineering Contradiction:

Improveendocannabinoid mobilizationVSAvoidamyloid beta oligomer suppression

Core Design Contradiction:

Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The PLC activator serves as an intermediary substance that mediates between amyloid beta oligomers and endocannabinoid mobilization. It restores the suppressed signaling pathway by activating phospholipase C, thereby overcoming the inhibitory effect of amyloid beta aggregates on endocannabinoid release.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention replaces the disrupted mechanical signaling mechanism (suppressed PLCβ activity) with an activated state through pharmacological intervention. The PLC activator substitutes for the normal signaling function that is compromised by amyloid beta oligomers, restoring endocannabinoid mobilization and synaptic plasticity.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Reliability

If synaptic plasticity is impaired, then memory function deteriorates, but PLCβ1 protein levels are reduced

Engineering Contradiction:

Improvesynaptic plasticityVSAvoidPLCβ1 protein level

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The invention changes the protein expression level parameter of PLCβ1 by using a PLC activator that restores normal protein levels in the hippocampus. This parameter restoration (from reduced to normal levels) directly improves synaptic plasticity and memory function by reestablishing the necessary signaling machinery.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The PLC activator composition effectively prevents or treats Alzheimer's disease by restoring synaptic plasticity and contextual fear memory in AD mice, suggesting its potential in delaying or suppressing the onset of the disease.

Implementation Method 1

a phospholipase C (PLC) activator as an active ingredient... confirmed that a phospholipase C (PLC) activator of the present invention restored the S-eCB mobilization suppressed by AβO

Methodology Applied

Scientific EffectPhospholipase C activation: Enzyme

Implementation Method 2

recovered the spike timing-dependent long-term potentiation (tLTP) of synaptic plasticity in the hippocampus impaired by AβO

Methodology Applied

Scientific EffectLong-term potentiation: Plasticity

Data Source

PatentUS20250049741A1Composition for preventing or treating alzheimer's disease comprising phospholipase c activator as an active ingredient

Publication Date: 2025.02.13 KOREA UNIV RES & BUSINESS FOUND

AI summary

The present invention relates to a composition for preventing or treating Alzheimer's disease, comprising a phospholipase C (PLC) activator as an active ingredient. A composition comprising the PLC activator of the present invention as an active ingredient restores the S-eCB mobilization suppressed by AβO, recovers the synaptic plasticity impaired by AβO, and not only recovers PLCβ1 protein levels to normal levels in AβO-treated mouse hippocampal slices and 5XFAD mouse hippocampal slices in the chronic stage of AD, but also recovers contextual fear memory impairment in AD mice, and thus is expected to be usefully used for preventing or treating Alzheimer's disease.